SLC9A1 and breast cancer: In breast cancer, AMSC-EVs can suppress the expression of SLC9A1 through miR-1236, resulting in the inhibition of the Wnt/β-catenin signaling pathway and thereby enhancing the sensitivity of breast cancer cells to DDP103.